PTO/SB08# (05-07)
Approved for use through 09/30/2007 OMB 0851-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Application Number 10815891
Filing Date 2004-03-31
Filing Date 2004-03-31
Filing Date 2004-03-31
Filing Date 3004-03-31
Filing Date 3004-

U.S. PATENTS

Examiner Cite Initial* Cite No Patent Number		Kind Code ¹	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear					
	1	6236731	B1	2001-05-22	Brennan et al					
	2	5701352		1997-12-23	Williamson, II					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information pl	lease click the	Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	d Publication Name of Pat e ¹ Date of cited Door		entee or Applicant Relevan		Columns,Lines where ant Passages or Relevan s Appear		
lf you wis	1 h to a	dd additional U.S. Pub		oplication citation			d button	Add		
If you wis Examiner Initial*	h to a	dd additional U.S. Publ Foreign Document Number ³		FOREIGN PAT	Publication		e or	Remove ages,Colu	or Relevant	
Examiner	h to a	Foreign Document	Country	FOREIGN PAT	Publication	Name of Patente Applicant of cited	e or	Remove Pages,Colo where Rele Passages	vant or Relevant	

Application Number 10815891 Filing Date 2004-03-31 Filing Date 2004-03-31 First Named Inventor Schneider et al. Art Unit Examiner Name Attorney Cooket Number 881-011758-US (PAR)

	3	0841836	EP	A2	1998-05-13	Delle Curti, Roberto		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Cite No							
	1							
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a								

See Knd Code of USPTO Pearl Documents at ware <u>USPTO_BOY</u> or MPEP 991.64. * Ester of this flavour has document, by the two-letter code (WIPO Standard ST.3). * For all replanes petral documents, are advantaged by an expensive period of the Emperor must preced the serial number of petral documents in the petral document of the Emperor must preced the serial number of petral document. The period of the Emperor must preced the serial number of petral documents and the petral documents of the Emperor must preced the serial number of the petral documents. * Applicant is to piece a credit must be period to the Emperor in the petral documents and the petral documents are preceded to the petral documents and the petral documents are petral documents. * Applicant is to piece a credit must be period to the petral document and the petral documents are petral documents. * Applicant is to piece a credit must be petral documents and the petral documents are petral documents. * Applicant is to piece a credit must be petral documents and the petral documents are petral documents. * Applicant is to piece a credit must be petral documents. * Applicant is petral document. * Applicant

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number 8

881-011758-US (PAR)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Places see 37 CFR 1 97 and 1 98 to make the appropriate selection(s):

▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/gcz44004/	Date (YYYY-MM-DD)	2007-08-01
Name/Print	Geza C. Zienier .lr	Registration Number	44.004

This collection of information is required by 3T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CPR 1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petertain and Tradenary Office. U.S. Operationed to Comment of Complete the form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Operationed to Comments. P.O. Box 1450, Alexandria, VA 2231.1450, D.D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 2231.1469.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.